Market Intelligence, Early Discovery Progress, and High-Purity Reagents for Epigenetic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ZNF160 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ZNF160 Recombinant Protein (Full-length / Zinc Finger Domain / Cys→Ala Mutant) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. DNA-binding competent and deficient controls included. |
View ZNF160 Products |
| Gene Delivery | ZNF160 Promise-ORF / Lentivirus Full-length ORF for stable cell lines, reporter assays, and ChIP validation. |
View ZNF160 Products |
| Benchmark Ab | Anti-ZNF160 (ChIP/ICC Grade) Recombinant monoclonal antibody for target engagement, localization, and pulldown studies. |
View ZNF160 Products |
| Validator | ZNF160 siRNA Set For knockdown verification and assay specificity controls. |
View ZNF160 Products |
| Related Target A | TRIM28 Corepressor partner (interacts directly with the ZNF160 KRAB domain). |
View TRIM28 Products |
| Related Target B | SETDB1 Histone methyltransferase recruited by the ZNF160-TRIM28 complex. |
View SETDB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Profiling | High-purity domain-specific recombinant proteins (e.g., KRAB domain) suitable for SPR/BLI binding kinetics. |
| ZNF Family Subfamily Counter-screening | Homolog panel proteins strictly verified by mass spec to ensure no cross-contamination. |
| Lack of Reliable Intracellular Controls | Sequence-verified Benchmark Antibodies and full-length Lentivirus included for stable expression. |
| False Positives in Degradation Assays | Validated siRNA included for genetic baseline specificity checks. |
Live ZNF160 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
ZNF160 represents an emerging class of intracellular transcription factor targets historically considered undruggable. As a KRAB-domain zinc finger protein (KRAB-ZNF), ZNF160 functions as a critical transcriptional repressor. Current discovery efforts are pivoting toward targeted protein degradation and DNA-binding disruption strategies. As first-generation epigenetic therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the ZNF160-TRIM28(KAP1) corepressor complex to reverse aberrant gene silencing in oncology and metabolic disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Preclinical Biotechs & Academia | Solid Tumors, Epigenetic Disorders | Ternary Complex Assay (Need high-purity recombinant ZNF160 and E3 ligases) |
| PPI Inhibitors | Academic Consortia | Hematological Malignancies | Binding Affinity (SPR/BLI) (Need KRAB domain specific proteins) |
| ASO / siRNA | Gene Therapy Startups | Refractory Cancers | Transcriptional Profiling (Need validated siRNA and Lentivirus cell lines) |